Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Standard Biotools (LAB) Invested Capital (2016 - 2025)

Historic Invested Capital for Standard Biotools (LAB) over the last 17 years, with Q3 2025 value amounting to $399.7 million.

  • Standard Biotools' Invested Capital fell 2656.65% to $399.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $399.7 million, marking a year-over-year decrease of 2656.65%. This contributed to the annual value of $471.7 million for FY2024, which is 60440.22% up from last year.
  • Per Standard Biotools' latest filing, its Invested Capital stood at $399.7 million for Q3 2025, which was down 2656.65% from $424.5 million recorded in Q2 2025.
  • Standard Biotools' 5-year Invested Capital high stood at $632.0 million for Q1 2024, and its period low was -$126.7 million during Q3 2023.
  • Over the past 5 years, Standard Biotools' median Invested Capital value was $109.4 million (recorded in 2021), while the average stood at $187.8 million.
  • In the last 5 years, Standard Biotools' Invested Capital tumbled by 46422.93% in 2023 and then soared by 158979.73% in 2024.
  • Over the past 5 years, Standard Biotools' Invested Capital (Quarter) stood at $148.8 million in 2021, then plummeted by 111.14% to -$16.6 million in 2022, then crashed by 464.23% to -$93.5 million in 2023, then surged by 604.4% to $471.7 million in 2024, then fell by 15.28% to $399.7 million in 2025.
  • Its Invested Capital was $399.7 million in Q3 2025, compared to $424.5 million in Q2 2025 and $454.6 million in Q1 2025.